Abstract
Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic progenitor cells which are characterized by relevant heterogeneity in terms of phenotypic, genotypic, and clinical features. Among the genetic aberrations that control disease development there are microRNAs (miRNAs). The present study aimed to investigate the role of miRNAs in diagnosis and prognosis of AML and it was designed as cross sectional study in patients with acute myeloid leukemia and normal individuals as control group, we determined: RNA yield and quality; and quantification of miRNA-203, miRNA-143, and miRNA-495 expression by Quantitative Real-Time PCR (qPCR) in the serum of AML patients and control groups. The study was conducted in period between December 2020 and September 2021 at the University of Babylon, College of Science, department of biology. In this case-control study, blood samples were collected from 115 AML patients (38 male and 77 female) and their ages ranged between 18 and 66 years , then, 60 patients were selected based on the quantity and natural color of their samples (28 male and 32 female), in addition to the 30 samples from healthy apparently subjects as a control group (11 male and 19 female), and this group matched with the patients groups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
